NEOG vs PHG vs CV Stock Comparison

Neogen, Koninklijke Philips and CapsoVision Prices as of Oct 26, 2026 Peers: Industry group
NEOG Neogen Corp
$12.21 -11.3% 1M +97.3% 1Y
Market cap
$2.72B
P/E
–
Revenue (TTM)
$883.99M
Div. yield
–
Diagnostic Equipment Healthcare
1 win
PHG Koninklijke Philips Nv
$26.56 +6.4% 1M -7.9% 1Y
Market cap
$25.07B
P/E
13.6x
Revenue (TTM)
$20.60B
Div. yield
–
Diagnostic Equipment Healthcare
8 wins
CV CapsoVision, Inc
$6.89 +3.6% 1M +40.6% 1Y
Market cap
$337.08M
P/E
–
Revenue (TTM)
$14.41M
Div. yield
–
Diagnostic Equipment Healthcare
1 win

Head to Head

10 decided of 12

Koninklijke Philips leads on 8 of the 12 questions below (Koninklijke Philips 8, CapsoVision 1, Neogen 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionNEOGPHGCVLeader
Larger companyMarket capitalisation $2.72B $25.07B $337.08M PHG
Cheaper on earningsLower P/E, profitable companies only -48.5x 13.6x -12.3x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 38.2x 13.4x — PHG
Faster revenue growthRevenue growth, trailing twelve months -0.3% +6.1% +14.6% CV
More profitableNet margin, trailing twelve months -6.3% 8.9% -190.2% PHG
Better return on capitalReturn on invested capital -0.2% 11.5% — PHG
Less leveragedLower net debt / EBITDA 5.4x 1.8x — PHG
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +97.3% -7.9% +40.6% NEOG
Better 5-year returnAnnualised price return, 5 years -21.6%/yr -10.8%/yr — PHG
Less volatileAnnualised volatility, 1 year 55.7% 28.8% 96.1% PHG
Higher overall scoreMean of the five percentile scores vs peers 57/100 80/100 36/100 PHG

Percentile Scorecard

NEOGPHGCV

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisNEOGPHGCV
Valuation 73 #63 of 228 98 #6 of 228 5 #217 of 228
Growth 49 #114 of 221 96 #11 of 221 42 #128 of 221
Profitability 61 #81 of 208 96 #10 of 208 23 #161 of 208
Financial Health 46 #129 of 239 31 #166 of 239 76 #59 of 239
Shareholder Returns 57 #59 of 137 79 #29 of 137 –
Overall 57 80 36
  • NEOG ranked among 248 companies in Medical Devices and Diagnostics
  • PHG ranked among 248 companies in Medical Devices and Diagnostics
  • CV ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodNEOGPHGCVSPY
1 month -11.3%+6.4%+3.6% -0.8%
3 months +30.7%+6.2%+4.2% +3.5%
6 months +29.2%-3.6%+8.2% +7.0%
Year to date +74.7%-1.9%-35.5% +12.2%
1 year +97.3%-7.9%+40.6% +13.0%
3 years -20.3%+43.6%— +86.3%
3 years, per year -7.3%+12.8%— +23.1%
5 years -70.3%-43.6%— +68.6%
5 years, per year -21.6%-10.8%— +11.0%
10 years -36.4%-11.6%— +258.0%
10 years, per year -4.4%-1.2%— +13.6%

Risk

MeasureNEOGPHGCVSPY
Volatility, 1Y 55.7%28.8%96.1% 12.7%
Downside volatility, 1Y 46.5%28.8%89.7% 12.7%
Beta vs S&P 500, 1Y 1.440.810.62 1.00
Return / volatility, 1Y 1.75-0.270.42 1.02
Max drawdown, 5Y -90.6%-75.6%-67.8% -25.4%
From 52-week high -12.7%-19.3%-52.2% -1.8%
52-week high $13.98$32.91$14.42 $779.14
52-week low $5.41$23.81$4.59 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleNEOGPHGCV
P/E now vs peer median -47.5xmedian 30.6x 13.7xmedian 30.6x -12.5xmedian 30.6x
P/S now vs peer median 3.0xmedian 3.0x 1.2xmedian 3.0x 23.9xmedian 3.0x
EV/EBITDA now vs peer median 29.5xmedian 17.5x 8.1xmedian 17.5x -12.5xmedian 17.5x
P/FCF now vs peer median 53.5xmedian 23.3x 5.9xmedian 23.3x —median 23.3x
P/B now vs peer median 1.3xmedian 2.4x 2.0xmedian 2.4x 26.2xmedian 2.4x
PEG now vs peer median 1.69median 0.87 0.32median 0.87 —median 0.87

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsNEOGPHGCV
Revenue $883.99M $20.60B $14.41M
Gross profit $418.98M $16.03B $7.55M
Operating income -$7.38M $2.65B -$27.71M
Net income -$56.10M $1.39B -$27.42M
Free cash flow $49.80M $4.34B –
R&D $19.76M $2.00B $20.51M
EPS (diluted) $-0.26 $1.91 $-0.55
Cash & equivalents $172.00M $2.04B –
Total debt $774.20M $9.51B –
Shares (diluted) 218.10M 962.50M 49.94M
Enterprise value $2.06B $14.18B $337.08M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricNEOGPHGCV
P/E -47.5x 13.7x -12.5x
P/FCF 53.5x 5.9x –
P/Operating cash flow 31.2x 9.6x –
P/S 3.0x 1.2x 23.9x
P/B 1.3x 2.0x 26.2x
P/Tangible book 3.4x 2.5x 26.2x
EV/EBITDA 29.5x 8.1x -12.5x
EV/EBIT -443.0x 12.4x -12.4x
EV/Revenue 3.7x 1.6x 23.9x
EV/FCF 65.6x 7.6x –
EV/Operating cash flow 38.3x 12.4x –
PEG (3Y EPS CAGR) 1.69 0.32 –

Growth

14 metrics
MetricNEOGPHGCV
Revenue growth (1Y) -0.3% 6.1% 14.6%
Revenue CAGR (3Y) -1.3% 2.3% –
Gross profit growth (1Y) 1.8% 82.4% 11.1%
Gross profit CAGR (3Y) -3.1% 6.7% –
Operating income growth (1Y) 99.3% 121.3% -36.1%
Operating income CAGR (3Y) -29.0% 52.0% –
Net income growth (1Y) 94.6% 293.5% -34.9%
Net income CAGR (3Y) -28.3% 35.6% –
EPS growth (1Y) 94.6% 539.4% 93.8%
EPS CAGR (3Y) -28.0% 42.2% –
Operating cash flow growth (1Y) -1.9% 116.7% –
Operating cash flow CAGR (3Y) 2.9% 53.6% –
Free cash flow growth (1Y) 1,631% 54.2% –
Free cash flow CAGR (3Y) 126.1% 45.6% –

Profitability

14 metrics
MetricNEOGPHGCV
Gross margin 47.4% 77.8% 52.4%
EBITDA margin 12.5% 19.8% -190.7%
Operating margin -0.8% 12.9% -192.3%
Pretax margin -7.7% 11.9% -190.1%
Net margin -6.3% 8.9% -190.2%
FCF margin 5.6% 21.1% –
Operating cash flow margin 9.6% 12.9% –
Return on equity -2.7% 12.7% -207.5%
Return on assets -1.7% 5.4% -149.3%
Return on invested capital -0.2% 11.5% –
Return on capital employed -0.2% 11.8% -209.8%
Asset turnover 0.3x 0.7x 0.8x
Cash conversion (OCF / net income) -1.5x 1.9x –
Stock comp / revenue 1.3% 0.7% –

Financial Health

11 metrics
MetricNEOGPHGCV
Debt / assets 23.4% 31.2% –
Debt / equity 0.4x 0.7x –
Net debt / EBITDA 5.4x 1.8x –
Debt / FCF 15.5x 2.2x –
Liabilities / assets 36.8% 57.1% 29.1%
Equity / assets 63.2% 42.9% 70.9%
Interest coverage – 6.2x –
Current ratio 3.9x 1.3x 3.4x
Quick ratio 2.1x 0.7x –
Cash ratio 1.2x 0.2x –
Altman Z-score 1.50 – 22.08

Shareholder Returns

7 metrics
MetricNEOGPHGCV
Dividend yield – 3.7% –
Net buyback yield -0.1% -0.5% –
Shareholder yield -0.1% 3.3% 0.0%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusNEOGPHGCV
Forward P/E 38.2xFY2026 13.4xFY2026 –
EPS, next fiscal year $0.32FY2026 $1.98FY2026 $-0.58FY2026
EPS growth, next FY 0.0%FY2026 +6.5%FY2026 –
EPS growth, the year after +31.3% -10.1% –
Revenue, next fiscal year $847.28MFY2026 $21.63BFY2026 $13.91MFY2026
Revenue growth, next FY -2.7%FY2026 +1.8%FY2026 +2.7%FY2026
Revenue growth, the year after -1.5% -8.2% +46.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersNEOGPHGCV
Held by institutions 100.0% 5.4% 10.2%
Institutions holding 315 363 50
Change in shares held, QoQ +1.6% +0.8% +27.6%
Institutions buying 151 266 36
Institutions selling 106 76 8
Buyers to sellers 1.42 3.50 4.50

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

NEOGPHGCV
NEOG 1.00 0.31 0.04
PHG 0.31 1.00 -0.02
CV 0.04 -0.02 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, NEOG, PHG and CV?

Koninklijke Philips (PHG) is the largest by market capitalisation: Neogen (NEOG) $2.72B, Koninklijke Philips (PHG) $25.07B, CapsoVision (CV) $337.08M.

Which company is growing faster?

CapsoVision (CV) grew revenue fastest over the trailing twelve months: Neogen (NEOG) -0.3%, Koninklijke Philips (PHG) +6.1%, CapsoVision (CV) +14.6%.

Which company is more profitable?

Koninklijke Philips (PHG) has the highest net margin (Neogen (NEOG) -6.3%, Koninklijke Philips (PHG) 8.9%, CapsoVision (CV) -190.2%). On return on invested capital, Koninklijke Philips (PHG) leads (Neogen (NEOG) -0.2%, Koninklijke Philips (PHG) 11.5%).

Which stock has performed better?

Over the past year Neogen (NEOG) returned the most: Neogen (NEOG) +97.3%, Koninklijke Philips (PHG) -7.9%, CapsoVision (CV) +40.6%. Over five years, Koninklijke Philips (PHG) compounded fastest (Neogen (NEOG) -21.6%/yr, Koninklijke Philips (PHG) -10.8%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Koninklijke Philips (PHG) has been the steadiest (Neogen (NEOG) 55.7%, Koninklijke Philips (PHG) 28.8%, CapsoVision (CV) 96.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, NEOG, PHG and CV?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Koninklijke Philips (PHG) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.